Patient groups ask Harsh Vardhan to come up with interim assistance for patients with rare diseases

Image
Press Trust of India New Delhi
Last Updated : Aug 27 2019 | 1:45 PM IST

Concerned over the 'delay' in the implementation of a national policy for treatment of rare diseases, patient advocacy groups have appealed to the Union Health Ministry to come up with an immediate interim arrangement to support treatment of patients diagnosed with such ailments.

Organization for Rare Disease India (ORDI) and Lysosomal Storage Disorder Support Society (LSDSS) have written to Union Health minister Harsh Vardhan asking him to provide an interim assistance till the National Policy Treatment of Rare Diseases (NPTRD) is formulated.

Vardhan recently directed ministry officials to expedite the process of formulating the NPTRD.

The policy was announced by the government in 2017 with a corpus of Rs 100 crore to provide financial aid for treatment of patients suffering from rare ailments.

However, in November last year, the health ministry put the policy and the corpus on hold, saying the focus was currently on communicable and non-communicable diseases.

Since then, there have been several representations to the central government from organisations including LSDSSI seeking reinstatement of the policy and funds to support patients.

Rare diseases are severe and chronic illnesses and are often life-threatening. Patients suffering from rare diseases, especially Lysosomal Storage Disorders (LSDs), often lead a very incapacitating life.

There are about 50 LSDs out of which only five have approved treatment options available in India.

Highlighting the government's priority to ensure healthcare for all, LSDSS said in its letter said that close to 190 patients, majority of them suffering from LSDs, sought support for treatment under the provisions of the earlier policy (which is now kept in abeyance).

"All these patients have been medically evaluated by the respective state technical committees and are eligible for funding for their treatment. Unfortunately, their hopes of any support for treatment have diminished, and are left with no tangible option.

"On behalf of all these patients, we would like to make a fervent appeal to you to make immediate interim arrangement till the policy formulation process is over for these group of patients so that they can continue with their treatment," the letter stated.

In an another letter, ORDI said, "As directed by the ministry of health earlier, more than 150-180 patients had applied for treatment support to the rare diseases cell and are eagerly looking forward to a positive immediate action from the ministry."
"Meanwhile, the Judiciary ordered the Health Ministry to provide the Interim treatment to 200 odd patients whose approved applications are pending with them. But see the height of callousness and indifferent approach of officials that they have not done anything till date. Nor they have come up with the reframed policy. Sadly, we are losing about five patients every month to these dreaded disorders in the absence of timely treatment."

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 27 2019 | 1:45 PM IST

Next Story